NasdaqGM:ORKABiotechs
Will Oruka Therapeutics (ORKA) New Director Hire Redefine Its Commercial Strategy Or Simply Refine It?
Earlier this month, Oruka Therapeutics announced that director Cameron Turtle resigned from its Board and was replaced by Christopher Martin, a veteran commercial leader who will serve as a Class II director, Compensation Committee Chair, and Audit Committee member through the 2026 annual meeting.
Investors may focus on Martin’s track record in preparing multiple first-time drug launches and his recent role at Verona Pharma, which was acquired by Merck for approximately US$10.00 billion...